Finding new treatments for high-risk pediatric and young adult cancers.
A Testing Program to Identify Novel Agents for Treatment of Pediatric and AYA High-Risk Sarcoma, Kidney and Liver Cancer
This study is looking for better treatment options for kids and young adults with tough cancers like sarcoma, kidney cancer, and liver cancer by testing new medicines alongside regular treatments to help those who haven't had success with standard care.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Science Center NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project ID | NIH-10888358 on NIH RePORTER |
What this research studies
This research focuses on developing new treatment options for children and young adults with high-risk cancers, specifically sarcoma, kidney cancer, and liver cancer. The team will use patient-derived xenografts (PDX), which are models created from actual patient tumors, to test various novel agents and combinations of therapies. By integrating these new treatments with existing chemotherapy and radiation, the goal is to improve outcomes for patients who have not responded to standard therapies. The research aims to identify effective treatments that can be translated into clinical practice for these vulnerable populations.
Who could benefit from this research
Good fit: Ideal candidates for this research are children and young adults diagnosed with high-risk sarcoma, kidney cancer, or liver cancer.
Not a fit: Patients with low-risk cancers or those who do not have sarcoma, kidney cancer, or liver cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for children and young adults suffering from high-risk cancers.
How similar studies have performed: Previous research using patient-derived xenografts has shown promise in identifying effective treatments for pediatric cancers, indicating that this approach has potential for success.
Where this research is happening
San Antonio, United States
- University of Texas Hlth Science Center — San Antonio, United States (Active)
Researchers
- Principal investigator: Kurmasheva, Raushan — University of Texas Hlth Science Center
- Study coordinator: Kurmasheva, Raushan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.